



Published in final edited form as:

Nature. 2009 February 26; 457(7233): 1103–1108. doi:10.1038/nature07765.

A mechanosensitive transcriptional mechanism that controls angiogenesis

Akiko Mammoto¹, Kip M. Connor², Tadanori Mammoto¹, Chong Wing Yung¹, Dongeun Huh¹, Christopher M. Aderman², Gustavo Mostoslavsky^{3,*}, Lois E. H. Smith², and Donald E. Ingber^{1,4}

¹Vascular Biology Program, Departments of Pathology & Surgery, Children's Hospital and Harvard Medical School, Boston, MA 02115

²Department of Ophthalmology, Children's Hospital and Harvard Medical School, Boston, MA 02115

³Department of Genetics, Harvard Medical School, Harvard Institute of Medicine, Boston, MA 02215, USA

⁴Wyss Institute for Biologically Inspired Engineering and Harvard School of Engineering and Applied Sciences, Cambridge, MA 02139

Abstract

Angiogenesis is controlled by physical interactions between cells and extracellular matrix as well as soluble angiogenic factors, such as VEGF. However, the mechanism by which mechanical signals integrate with other microenvironmental cues to regulate neovascularization remains unknown. Here we show that the Rho inhibitor, p190RhoGAP, controls capillary network formation *in vitro* and retinal angiogenesis *in vivo* by modulating the balance of activities between two antagonistic transcription factors – TFII-I and GATA2 – that govern gene expression of the VEGF receptor, *VEGFR2*. Moreover, this novel angiogenesis signaling pathway is sensitive to extracellular matrix elasticity as well as soluble VEGF. This is the first known functional cross-antagonism between transcription factors that controls tissue morphogenesis, and that responds to both mechanical and chemical cues.

Keywords

VEGFR2; p190RhoGAP; TFII-I; GATA2; mechanotransduction; angiogenesis; capillary endothelial cell

Deregulation of angiogenesis – the growth of blood capillaries – contributes to development of many diseases, including cancer, arthritis and blindness^{1, 2}. FDA-approved angiogenesis inhibitors solely target the oxygen-sensitive vascular endothelial growth factor, VEGF; however, neovascularization is also controlled by other microenvironmental signals, including mechanical forces conveyed by extracellular matrix (ECM). For example, although capillary development is driven by angiogenic mitogens, cell sensitivity to these soluble cues can be

Address correspondence to: Donald E. Ingber, M.D., Ph.D. KFRL 11.127, Vascular Biology Program, Departments of Pathology & Surgery, Children's Hospital / Harvard Medical School, 300 Longwood Ave. Boston, MA 02115, ph: 617-919-2223, fax: 617-730-0230, em: E-mail: donald.ingber@childrens.harvard.edu.

*Present address: Department of Medicine, Boston University School of Medicine, Boston, MA 02115

Author Contributions: A.M. conceived of the experiments, and performed experiments, designed research and analyzed data with assistance from K.M.C., T.M., C.W.Y., D.H., C.M.A., G.M., L.E.H.S. and D.E.I. A.M. wrote the manuscript with D.E.I., with input from L.E.H.S.

modulated by physical interactions between cells and ECM that alter cell shape and cytoskeletal structure³⁻⁸. Similar changes in capillary cell shape and function can be produced by changing ECM elasticity, adhesivity or topography, applying mechanical stresses, or altering cell-generated traction forces³⁻⁸. Mechanical tension also stimulates capillary growth and vascular remodeling *in vivo*⁹, and regional variations of ECM mechanics and cell shape appear mediate how neighboring cells undergo localized differentials of growth and differentiation that drive three-dimensional (3D) tissue pattern formation^{10, 11}. But the mechanism by which mechanical signals conveyed by ECM converge with those elicited by growth factors to control gene transcription required for angiogenic control remains unknown.

VEGF and its receptor VEGFR2 are of particular importance in angiogenesis because they are essential for normal blood vessel development^{12, 13}, and deregulation of these factors leads to various pathological conditions^{1, 2, 14}. We therefore investigated the role of VEGF and VEGFR2 in the mechanism by which these mechanical forces regulate capillary development. Analysis of cellular mechanotransduction during angiogenesis has revealed that the small GTPase, Rho, mediates growth control *in vitro*^{10, 15}, as well as blood vessel development *in vivo*⁹, by modulating the mechanical force balance that governs cell shape. Stress-induced distortion of the capillary cell cytoskeleton regulates Rho activity by controlling its upstream inhibitor, p190RhoGAP¹⁶. p190RhoGAP was shown to bind to the transcription factor TFII-I and sequester it in the cytoplasm of fibroblasts¹⁷, and TFII-I is a multifunctional transcription factor that regulates *VEGFR2* expression in large vessel endothelial cells^{18, 19}. Although it remains unknown whether it plays a role in angiogenesis, TFII-I deletions are associated with cardiovascular defects²⁰. These findings raise the possibility that TFII-I might also contribute to intracellular signaling mechanisms triggered by mechanical forces during vascular network formation.

p190RhoGAP and TFII-I regulate VEGFR2

To explore whether p190RhoGAP modulates vascular development by altering gene transcription, we knocked down *p190RhoGAP* in human microvascular endothelial (HMVE) cells using siRNA. TFII-I protein levels were approximately 1.5 times higher in the nuclear fraction of knockdown cells (Supplementary Fig. S2a), and this was confirmed by fluorescence microscopy (Supplementary Fig. S2b). As first shown in fibroblasts¹⁷, we found that p190RhoGAP co-precipitates with TFII-I (and vice versa) (Supplementary Fig. S2c), suggesting that p190RhoGAP may also bind TFII-I and sequester it in the cytoplasm of human capillary cells.

TFII-I upregulates VEGFR2 protein expression in human aortic endothelial cells by binding to the *VEGFR2* promoter¹⁸. But *TFII-I* knockdown in our HMVE cells increased (rather than decreased) *VEGFR2* mRNA and protein levels by 2- to 3-fold relative to control cells, and overexpressing *TFII-I* (delta isoform²¹) using lentiviral transduction produced the opposite effect (Fig. 1a, Supplementary Fig. S3a). This may be due to the fact that macrovascular and microvascular endothelial cells undergo distinct morphogenetic programs (produce large tubes versus branching capillaries).

TFII-I binds to the Inr region of the *VEGFR2* gene promoter, and smaller portions of this promoter (human *VEGFR2*: -225 to +268, -570 to +268, and -780 to +268) have similar or greater activity compared to the full length promoter (4kb)^{18, 22}. When these various *VEGFR2* promoters were characterized using a luciferase assay in human umbilical vein endothelial (HUVE) cells, *TFII-I* knockdown increased, and overexpression of *TFII-I* using DNA transfection decreased, *VEGFR2* promoter activity by 1.5 to 2-fold and one-fifth normal levels, respectively (Supplementary Fig. S3b). The promoter-less pGL3 basic reporter showed no promoter activity (not shown). Moreover, mutagenesis of the *VEGFR2* Inr (-780+268;

780MUT) decreased promoter activity in both control and *TFII-I* knockdown cells (Supplementary Fig. S3b), confirming that TFII-I decreases *VEGFR2* promoter activity through the Inr region. Importantly, the specificity of these effects of *TFII-I* knockdown were confirmed by demonstrating that reconstitution of *TFII-I* can reverse these effects (Supplementary Fig. S3c).

We next asked whether p190RhoGAP stimulates *VEGFR2* expression by restricting nuclear translocation of TFII-I (Supplementary Fig. S2a,b). *TFII-I* knockdown increased, and *p190RhoGAP* knockdown decreased, *VEGFR2* promoter activity (-780+268) relative to control cells (Supplementary Fig. S3d). The double knockdown of *p190RhoGAP* and *TFII-I* exhibited the same stimulation as observed in the *TFII-I* knockdown cells (Supplementary Fig. S3d). However, *p190RhoGAP* knockdown did not decrease *VEGFR2* mRNA and protein levels; in fact, it increased *VEGFR2* protein levels (Fig. 1b, Supplementary Fig. S3d). Moreover, *p190RhoGAP* and *TFII-I* double knockdown produced similar or slightly higher levels of *VEGFR2* mRNA and protein expression (Fig. 1b, Supplementary Fig. S3d) compared to either *p190RhoGAP* or *TFII-I* knockdown alone. These results raised the intriguing possibility that an antagonist of TFII-I activity might exist that also contributes to p190RhoGAP-dependent control of *VEGFR2* expression.

GATA2 upregulates VEGFR2

GATA2 is another transcription factor that binds the *VEGFR2* promoter and regulates its activity^{23, 24}. Because many GATA family members antagonize the effects of other transcription factors at promoter sites²⁵⁻²⁸, we explored whether GATA2 mediates p190RhoGAP-dependent control of *VEGFR2* expression by opposing TFII-I activity. When *p190RhoGAP* was knocked down, GATA2 levels in the nucleus increased dramatically (> 10-fold) relative to control cells even though total GATA2 levels remained the same, as shown by immunoblotting (Supplementary Fig. S3e) and fluorescence microscopy (Fig. 1c). p190RhoGAP also co-immunoprecipitated with GATA2 and vice versa (Supplementary Fig. S3f). Importantly, this increase in nuclear GATA2 was significantly higher than the 1.5-fold increase in nuclear TFII-I produced using *p190RhoGAP* siRNA (Supplementary Fig. S2a,b), suggesting that p190RhoGAP binds and sequesters GATA2 in the cytoplasm more efficiently than TFII-I in capillary cells. *GATA2* knockdown using siRNA decreased *VEGFR2* promoter activity, as well as levels of mRNA and protein (Supplementary Fig. S4a,b) as previously observed²³, while *GATA2* overexpression produced the opposite effects. These effects of *GATA2* siRNA on *VEGFR2* promoter activity and protein expression were specific as they were reversed by *Gata2* reconstitution (Supplementary Fig. S3c). Interestingly, *p190RhoGAP* knockdown increased the expression of *VEGFR2* mRNA and protein, and double knockdown with *GATA2* inhibited these effects (Fig. 1d, Supplementary Fig. S4c). Thus, GATA2 appears to upregulate *VEGFR2* promoter activity and mediate the effects of p190RhoGAP on *VEGFR2* gene expression in capillary cells. However, knockdown of *p190RhoGAP*, which releases more GATA2 than TFII-I and increases *VEGFR2* expression, did not increase *VEGFR2* promoter activity (Supplementary Fig. S3d). This may be because cellular *TFII-I* levels are 5 times higher than *GATA2* levels (not shown). We also measured *VEGFR2* promoter activity using only a portion of its promoter, and hence, TFII-I and GATA2 also may exert regulatory activities at other promoter sites; alternatively, p190RhoGAP might elicit signals that influence mRNA stability.

We next asked whether GATA2 and TFII-I directly antagonize each other. Simultaneous knockdown of *TFII-I* and *GATA2* abrogated each other's effects on *VEGFR2* promoter activity (Fig. 1e), mRNA production (Fig. 1f) and protein expression levels (Supplementary Fig. S4e), and simultaneous overexpression of *TFII-I* and *GATA2* produced similar effects (Supplementary Fig. S4d,e). These effects were specific for *VEGFR2* as knockdown of *TFII-*

I or *GATA2* did not alter expression of *VEGFR1* or *VEGFR3* in HMVE cells (Supplementary Fig. S5a). Importantly, although p190RhoGAP is a Rho inhibitor, altering Rho activity with constitutively active RhoA, membrane-permeable C3 exoenzyme or siRNA directed to another Rho-inhibiting RhoGAP (*p73RhoGAP*)²⁹ did not change *VEGFR2* mRNA or protein levels (Supplementary Fig. S5b,c). Thus, p190RhoGAP appears to control *VEGFR2* expression solely by its ability to sequester these transcription factors.

Analysis of this mechanism of functional cross-antagonism revealed that *GATA2* and TFII-I associate with each other, as *GATA2* co-immunoprecipitated with TFII-I, and vice versa (Supplementary Fig. S6a). Furthermore, *GATA2* even binds to TFII-I in *p190RhoGAP* knockdown cells and to p190RhoGAP in *TFII-I* knockdown cells (Supplementary Fig. S6b). These results suggest that the various heterodimeric combinations of TFII-I, *GATA2*, and p190RhoGAP exist in separate pools, and that these heterodimers then associate to form a larger ternary complex (Supplementary Fig. S1).

Chromatin immunoprecipitation (ChIP) analysis revealed that *TFII-I* knockdown cells exhibited increased recruitment of *GATA2* to the *GATA* binding site (-150+150) compared to control cells and vice versa (Fig. 1g), whereas control IgG did not immunoprecipitate these DNAs (Fig. 1g). *p190RhoGAP* knockdown decreased recruitment of TFII-I, but not *GATA2*, to this promoter site, which resulted in a relative net increase in *GATA2* recruitment to this site (Supplementary Fig. S6c). TFII-I and *GATA2* therefore compete with each other for occupancy of a common region of the *VEGFR2* promoter, which is controlled by p190RhoGAP.

Mechanical control of *VEGFR2*

Soluble growth factors, integrin binding to ECM and mechanical distortion of the cytoskeleton all regulate p190RhoGAP activity in cells³⁰. Cell binding to growth factors and adhesive contact formation with ECM also control *VEGFR2* expression^{31, 32}, and soluble mitogens (5% serum plus VEGF, bFGF and PDGF) increase nuclear translocation of TFII-I and *GATA2* in HMVE cells (Supplementary Fig. S7a). We therefore next explored whether changes in mechanical interactions between cells and ECM regulate this pathway as well. When HMVE cells were cultured in the absence of mitogens on fibronectin-coated polyacrylamide gels with different elasticity (Young's moduli of 150 to 4000Pa), they appeared round on the soft gels, while they flattened on the stiffer gels, as previously observed^{33, 34}, which is based on differences in their ability to physically resist cell traction forces^{8, 33, 34}. Nuclear *GATA2* levels were significantly higher in cells on the stiffer gels, whereas nuclei exhibit similar high levels of TFII-I regardless of ECM stiffness (Fig. 2a), and similar results were obtained in the presence of multiple soluble factors or VEGF alone (Supplementary Fig. S7b). Moreover, *VEGFR2* mRNA and protein levels were higher in cells on the stiffer (4000 Pa) gels (Fig. 2b, Supplementary Fig. S7c). Interestingly, this relatively stiff, but still compliant, ECM gel appeared to support optimal responsiveness of this signaling pathway as *VEGFR2* mRNA and protein levels were significantly lower in cells cultured on rigid glass ECM substrates (Fig. 2b, Supplementary Fig. S7c). ECM elasticity may therefore regulate *VEGFR2* expression preferentially via *GATA2*, particularly over the stiffness range analyzed in this study.

Further analysis revealed that *TFII-I* knockdown restored *VEGFR2* expression in cells on soft gels to levels similar to those in cells on stiff gels, and double knockdown with *GATA2* (which decreases *VEGFR2* expression) abrogated *TFII-I*'s effects (Fig. 2c, Supplementary Fig. S7d). *p190RhoGAP* knockdown also increased expression of *VEGFR2* mRNA and protein, and double knockdown with *GATA2* inhibited these effects on soft gels (Fig. 2d, Supplementary Fig. S7d). These data indicate that p190RhoGAP and the mutually antagonistic TFII-I and

GATA2 transcription factors mediate the effects of ECM elasticity on *VEGFR2* expression in these cells, which is preferentially shifted to GATA2 on stiffer gels.

Transcriptional control of angiogenesis

We next explored the functional relevance of this antagonism between GATA2 and TFII-I by analyzing capillary cell migration and differentiation (tube formation) *in vitro*. When HMVE cells were transfected with *TFII-I* siRNA and analyzed using the Transwell migration assay, VEGF-stimulated cell motility increased by 2-fold, whereas this induction was prevented by knocking down *GATA2* simultaneously with *TFII-I* (Fig. 3a). The VEGFR2 kinase inhibitor SU5416 totally inhibited the migration of these cells (Fig. 3a), confirming that these effects are mediated by VEGFR2 signaling. Moreover, *GATA2* overexpression increased VEGF-induced cell migration by 3-fold, and simultaneous overexpression of *GATA2* and *TFII-I* abolished these effects (Fig. 3a). These effects were specific in that reconstitution of *TFII-I* or *Gata2* reversed the effects of knocking down *TFII-I* or *GATA2*, respectively (Supplementary Fig. S8a).

We then studied capillary tube formation by HMVE cells cultured within the ECM gel, Matrigel, which supports angiogenesis in part because of its flexibility. Tube formation was stimulated by VEGF in a dose-dependent manner, whereas bFGF and PDGF were ineffective, and the effects of VEGF were inhibited by SU5416 (Supplementary Fig. S8b). *GATA2* knockdown and *TFII-I* overexpression suppressed VEGF-stimulated capillary development, and once again either knocking down or overexpressing both transcription factors simultaneously negated these effects (Fig. 3b, Supplementary Fig. S8c). *TFII-I* knockdown or *GATA2* overexpression alone did not produce significant effects on tube formation, apparently because it was already optimally stimulated under these conditions (Fig. 3b); knockdown or overexpression of *p190RhoGAP* also did not alter tube formation (Supplementary Fig. S8d). Thus, functional antagonism between GATA2 and TFII-I at the level of *VEGFR2* transcription translates into biologically relevant changes in capillary cell behavior that are required for formation of 3D capillary networks.

Control of angiogenesis in vivo

We next examined whether ECM mechanics governs vessel formation *in vivo* using a modified Matrigel implant assay. Maximal levels of cell infiltration, capillary blood vessel formation, and VEGFR2 expression were observed in Matrigel with intermediate stiffness (800 Pa) compared to cells in more or less rigid gels (900 or 700 Pa, respectively) (Fig. 4a,c and Supplementary Fig. S9a,b). VEGFR2, GATA2, and TFII-I all localized within cells lining CD31-positive staining microvessels (Supplementary Fig. S9c). The finding that the optimal ECM stiffness required for angiogenesis *in vivo* (800 Pa) was different than that observed *in vitro* (4000 Pa) is likely due to different requirements by cells when cultured on 2D ECM versus within a 3D ECM gel; it also may relate to how the Matrigel is remodeled over time *in vivo*.

We next performed siRNA-mediated gene knockdown in the *in vivo* Matrigel assay. Interestingly, *TFII-I* knockdown increased cell infiltration, capillary vessel formation and VEGFR2 expression by cells in the soft gels so that it mimicked the behavior of cells on the intermediate stiffness gel, whereas *Gata2* knockdown produced the opposite effects (Fig. 4b,d and Supplementary Fig. S10a), and *p190RhoGAP* knockdown also increased the level of vessel formation in the soft gels (Supplementary Fig. S10b). These results indicate that TFII-I, GATA2, and p190RhoGAP mediate the signaling effects of ECM mechanics on vessel formation *in vivo*.

To unequivocally confirm the functional and clinical relevance of regulatory interactions between TFII-I, GATA2, and p190RhoGAP, we modulated their expression in the neonatal

mouse retina because angiogenesis in this growing organ is tightly regulated by VEGF and its receptors^{14, 35, 36}. TFII-I, GATA2, and VEGFR2 localized to the three layers of the retina where blood vessels are located in postnatal day 15 mice (Supplementary Fig. S11a,b). Consistent with *in vitro* data, knocking down *TFII-I* using intravitreal injection of siRNA to p14 mice resulted in increased *Vegfr2* expression and the appearance of highly tortuous dilated vessels and a significant increase in vascular density in the retina, whereas *Gata2* knockdown suppressed *Vegfr2* expression, disrupted capillary network formation and decreased vascular density (Fig. 5a, Supplementary Fig. S12a,b). Knockdown of *p190RhoGAP* also increased *Vegfr2* expression and vessel density, but it resulted in a slightly different capillary growth pattern, perhaps in part because of its known effects on vascular permeability³⁷ (Fig. 5a and Supplementary Fig. S12a,b). Similar effects were observed in earlier (P5) retina that contain rapidly growing microvessels (Supplementary Fig. S13). Furthermore, overexpression of *TFII-I* and *GATA2* produced opposite effects on vascular density in P14 retina, and simultaneous overexpression of both factors abolished these effects, confirming our *in vitro* findings (Fig. 5b and Supplementary Fig. S12c). Knockdown of *p190RhoGAP* or *TFII-I* did not significantly change *Vegf* expression levels in the retina, whereas *Gata2* knockdown increased (rather than decreased) its expression (Supplementary Fig. S12d). The decrease of *Vegfr2* expression appears to be sufficient to abrogate this *Vegf* response in *Gata2* knockdown retina, and thereby inhibit angiogenesis. Hence, p190RhoGAP controls *Vegfr2* expression and vascular development by modulating the balance between TFII-I and GATA2 activities such that TFII-I activity dominates (and *Vegfr2* expression is suppressed) in retina.

Discussion

Transcription factors change their activities in a spatiotemporal manner during development, and thereby specify cell fate^{38, 39}. Here we show that p190RhoGAP, which has been shown to be regulated by growth factors, ECM binding and cytoskeletal distortion also controls *VEGFR2* expression, as well as angiogenesis *in vitro* and *in vivo*, by altering the balance between two mutually antagonistic transcription factors: TFII-I and GATA2 (Supplementary Fig. S1). Moreover, we demonstrate that p190RhoGAP and this downstream transcriptional control mechanism are controlled by mechanical signals conveyed by variations in ECM elasticity. This mechanism is analogous to other developmental mechanisms used by hematopoietic cells and mammary epithelium³⁸⁻⁴⁰; however, this is the first demonstration that transcriptional cross-antagonism can govern histodifferentiation and tissue morphogenesis, and be sensitive to mechanical as well as chemical cues.

Our data suggest that an appropriate level of ECM stiffness may be required for optimal *VEGFR2* expression and vascular development *in vitro* and *in vivo*. In fact, the fates of different cell types are exquisitely sensitive to distinct ECM elasticity values that often match those exhibited by their host tissues⁴¹. Abrupt local changes in ECM mechanics also accompany the switch between active growth and quiescent differentiation of functional capillary networks in living tissues⁴². Cell rounding suppressed p190RhoGAP activity within 1 to 2 hours by altering its binding to the cytoskeletal protein, filamin¹⁶. A similar cytoskeleton-based effect could mediate the effect of ECM elasticity on p190RhoGAP activity at later times, and thereby control the TFII-I:GATA2 balance and *VEGFR2* transcription. Since *VEGFR2* is expressed in neurons as well as in endothelial cells in retina, some of the effects of gene knockdown we observed may not be specific to capillary cells. But even these alterations might be relevant for control of vascular development because neuron-vessel interactions are indispensable for normal microvasculature function and patterning⁴³.

In summary, these data reveal a previously unknown mechanosensitive signaling pathway that controls *VEGFR2* promoter activity and expression, and which represents a point of convergence for all three classes of microenvironmental signals that regulate capillary

morphogenesis. Development of specific modifiers of this pathway could therefore lead to novel therapeutic approaches for various angiogenesis-dependent diseases, including proliferative retinopathy, arthritis, and cancer in the future.

Methods Summary

Expression of *TFII-I*, *GATA2*, and *VEGFR2* were evaluated by qRT-PCR and immunoblotting. A luciferase reporter assay was used to measure *VEGFR2* promoter activity. To test the effects of *TFII-I* and *GATA2* on *VEGFR2* expression and angiogenesis *in vitro*, siRNA-mediated knockdown or lentiviral transduction was performed in HMVE cells. *In vitro* analysis of angiogenesis was carried out using Transwell migration and Matrigel tube formation assays, and similar results were obtained using both native and growth factor-reduced forms of Matrigel. A subcutaneous Matrigel angiogenesis assay was used to analyze the effects of ECM mechanics on capillary formation *in vivo*. Retinal vessel formation was also studied in newborn C57BL/6 mice, and gene expression was manipulated in whole living retina by intravitreal injection of siRNA or DNA into the eye at P5 or P14.

Methods

Materials

Anti-GATA2 polyclonal antibody was from Abcam (Cambridge, MA); anti-HA monoclonal antibody from Covance (Princeton, NJ); monoclonal antibodies against *TFII-I*, p190RhoGAP, PECAM (CD31), and paxillin from Transduction laboratory (Lexington, KY); anti-GAPDH antibody from Chemicon (Temecula, CA); anti-lamin monoclonal antibody from Upstate (Lake Placid, NY); anti-*VEGFR2* antibody from Cell Signaling (Danvers, MA); and anti-myc antibody from Santa Cruz (Santa Cruz, CA). Protein G-sepharose was from Amersham-Pharmacia (Uppsala, Sweden) and SU5416 was from Calbiochem (San Diego, CA). VEGF-A was from NIH; bFGF and PDGF were from Roche (Basel, Switzerland) and Biovision (Mountain View, CA) respectively. Cell permeable Rho inhibitor (C3 exoenzyme) was from Cytoskeleton (Denver, CO). HMVE and HUVE cells (Cambrex, Walkersville, MD) were cultured in EBM2 medium containing 5% FBS and growth factors (VEGF, bFGF, and PDGF) for all experiments¹⁶ except the nuclear translocation assays in which we used EBM2 with 0.3% serum. Cells were plated on plastic dishes for molecular biochemical assays, and on fibronectin-coated glass coverslips for cell staining, except for experiments using flexible substrates.

Plasmid construction and gene knockdown

pGL3-*VEGFR2*-225 (-225+268), -570 (-570+268), -780 (-780+268) were constructed using the reverse transcription (RT)-PCR with genomic DNA from HUVE cells, and subcloned into pGL3 vector (Promega) at the *SacI/XhoI* sites. For pGL3-*VEGFR2*-780Inr-MUT, the Inr (CACT to GTGC) was point mutated using the QuickChange mutagenesis kit (Stratagene, La Jolla, CA). For lentivirus construction, human *myc-TFII-I* (delta isoform), *HA-GATA2*, and *HA-p190RhoGAP* were constructed by PCR using template plasmids from Open Biosystems (Huntsville, AL) and H. Sabe (OBI, Osaka, Japan). For retrovirus construction, mouse *myc-TFII-I* (gamma isoform) and *HA-Gata2* were constructed using template plasmids from Open Biosystems and T. Nakano (Osaka University, Osaka, Japan), respectively. To generate delta isoform of mouse *TFII-I*, 256-274 and 294-314aa were deleted from the gamma isoform. Construction of constitutively active RhoA and generation of viral vectors were previously described³⁷. For gene knockdown, siRNA transfection was performed as described¹⁶. siRNA sequences are shown in Supplementary Table S1.

Biochemical Methods

For luciferase reporter assays, HUVE cells were transfected using Superfect (QIAGEN) and assayed using Dual-Luciferase reporter assay kit (Promega). Luciferase activity was measured in duplicate using a luminometer (TD20/20, Turner Designs). Cytoplasmic and nuclear cell extracts were prepared with a Nuclear Extraction Kit (Chemicon).

Molecular biological methods

Quantitative RT-PCR was performed with the Quantitect SYBR Green RT-PCR kit (QIAGEN) using ABI7300 real-time PCR system (Applied Biosystems, Foster City, CA); β 2 microglobulin or cyclophilin controlled for cDNA content. The primers used are shown in Supplementary table S2. For ChIP assay, DNA from HMVE cells transfected with control or *TFII-I* siRNA was immunoprecipitated with the GATA2 antibody or control immunoglobulin (Jackson Immuno Research), or vice versa, according to the manufacturer instructions (Active Motif). GATA2- and TFII-I-binding region was amplified using primers, 5'-GTAAATGGGCTTGGGGAGCTG-3' and 5'-GGCGGCTGCAGGGGCGTCT-3'′.

Cell analysis methods

Flexible polyacrylamide gel culture substrates were prepared as described^{34, 44} and coated with fibronectin (1 μ g/cm²). Substrate flexibility was controlled by varying the acrylamide (2–4%) and the bis-acrylamide (0.1–0.5%) concentration; the Young's modulus (stiffness) was determined as described⁴⁵. HMVE cells were cultured for 6 hrs on the gels and immunostaining was performed and analyzed using confocal Leica SP2 microscope¹⁵. For cell migration assay, Transwell membranes (Costar, NY) were coated with 0.5% gelatin, and cells were seeded (10⁵ cells/100 μ l) with 0.3% FBS/EBM2. Cells were stained with Giemsa solution 16 h later, and counted in 10 random fields (\times 400). For the *in vitro* angiogenesis assay, HMVE cells (10⁴ cells/150 μ l of EBM-2) were plated on MatrigelTM (BD biosciences), and incubated for 12–16 hrs in the presence of VEGF (10 ng/ml); tube formation was assessed in 10 random fields (4 \times).

In vivo Matrigel implantation assay

All animal studies were reviewed and approved by the animal care and use committee of Children's Hospital Boston. Matrigel plugs with different elasticity were cast in 4 \times 4mm (ID \times H) polydimethylsiloxane (PDMS) molds and incubated at 37°C overnight before implanting them subcutaneously on the backs of C57BL/6 mice. The stiffness of the Matrigel was modulated over a narrow range (i.e., without making it rigid) by altering ECM protein cross-linking using a microbial transglutaminase (2.5–20 U/g; Ajinomoto, Japan)⁴⁶. The storage modulus (G') of the gels was measured with an AR-G2 rheometer (TA Instruments) using a standard 20 mm aluminum parallel plate (1Hz, 1% strain, 37°C). The Young's modulus for an equivalent polyacrylamide gel was calculated by $E = 2 \cdot G'(1 + \nu)$ using an average Poisson's Ratio (ν) of 0.5. After 7 days, the PDMS molds containing the gel plugs were harvested, fixed, and cryosectioned. H&E staining and immunostaining were performed as described^{15 47}. Stacks of optical sections (20 μ m thick) were compiled to form 3D images using Velocity4.4 (Improvision, PerkinElmer). Vessel formation was evaluated by counting the number of vessels that stained positive for fluorescein-conjugated ConA injected into the tail vein or VEGFR2 in 5 different areas (n=6), individual cell nuclei were identified by DAPI staining. Cell recovery solution (BD Biosciences) was used to collect cells from the recovered Matrigel plugs. In some studies, siRNA (7 μ g) was mixed into the Matrigels and 10 μ g of additional siRNA was injected into the implanted Matrigel after 3 days (n=6); the same amount of scrambled siRNA was used as a control. Gene knockdown was evaluated by counting the number of cells expressing each gene in the five different regions.

In vivo analysis for retinal vessel formation

For gene knockdown in living retina, siRNA (0.5 μ g) for each gene was injected intravitreally into one eye of C57BL/6 mouse at P5 or P14, and the same amount of control siRNA was injected to the other eye. To overexpress genes, the complex of DNA (0.5 μ g) for *TFII-I* and/or *GATA2* and jetPEI transfection reagent (Polyplus transfection, CA) was injected to the eye at P14. Vascular network formation in the retina was assessed 2 days after injection using flat-mounted, fluorescein-conjugated isolectin-staining and immunohistochemical analysis (n=7). Retinal RNA was purified and gene expression was quantified using qRT-PCR (n=7). Quantification of vessel density was performed with Adobe photoshop.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank T. Polte, E. Pravda, M. de Bruijn, and K. Johnson for their technical suggestions and assistance, T. Nakano and H. Sabe for providing plasmid, NIH for providing VEGF, and D. Weitz for providing assistance with Rheometry measurements. This work was supported by funds from NIH (to D.E.I., L.E.H.S. and K.M.C.), V. Kann Rasmussen Foundation (to L.E.H.S.), Children's Hospital Mental Retardation and Developmental Disabilities Research Center (to L.E.H.S.), a Research to Prevent Blindness Lew Wasserman Merit Award (to L.E.H.S.), AHA (to A.M.), and a Children's Hospital House Officer Development Award (to A.M.); D.E.I. is a recipient of a DoD Breast Cancer Innovator Award.

References

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003;9:669–76. [PubMed: 12778165]
2. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. *Annu Rev Med* 2007;58:491–504. [PubMed: 17052163]
3. Ingber DE, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis *in vitro*: role of extracellular matrix. *J Cell Biol* 1989;109:317–30. [PubMed: 2473081]
4. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE. Geometric control of cell life and death. *Science* 1997;276:1425–8. [PubMed: 9162012]
5. Dike LE, et al. Geometric control of switching between growth, apoptosis, and differentiation during angiogenesis using micropatterned substrates. *In vitro Cell Dev Biol Anim* 1999;35:441–8. [PubMed: 10501083]
6. Parker KK, et al. Directional control of lamellipodia extension by constraining cell shape and orienting cell tractional forces. *Faseb J* 2002;16:1195–204. [PubMed: 12153987]
7. Matthews BD, Overby DR, Mannix R, Ingber DE. Cellular adaptation to mechanical stress: role of integrins, Rho, cytoskeletal tension and mechanosensitive ion channels. *J Cell Sci* 2006;119:508–18. [PubMed: 16443749]
8. Kumar S, et al. Viscoelastic retraction of single living stress fibers and its impact on cell shape, cytoskeletal organization, and extracellular matrix mechanics. *Biophys J* 2006;90:3762–73. [PubMed: 16500961]
9. Moore KA, et al. Control of basement membrane remodeling and epithelial branching morphogenesis in embryonic lung by Rho and cytoskeletal tension. *Dev Dyn* 2005;232:268–81. [PubMed: 15614768]
10. Huang S, Ingber DE. The structural and mechanical complexity of cell-growth control. *Nat Cell Biol* 1999;1:E131–8. [PubMed: 10559956]
11. Folkman J, Moscona A. Role of cell shape in growth control. *Nature* 1978;273:345–9. [PubMed: 661946]
12. Folkman J, Kalluri R. Cancer without disease. *Nature* 2004;427:787. [PubMed: 14985739]
13. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. *Sci STKE* 2001 2001:RE21.

14. Wong CG, Rich KA, Liaw LH, Hsu HT, Berns MW. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. *Curr Eye Res* 2001;22:140–7. [PubMed: 11402391]
15. Mammoto A, Huang S, Moore K, Oh P, Ingber DE. Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition. *J Biol Chem* 2004;279:26323–30. [PubMed: 15096506]
16. Mammoto A, Huang S, Ingber DE. Filamin links cell shape and cytoskeletal structure to Rho regulation by controlling accumulation of p190RhoGAP in lipid rafts. *J Cell Sci* 2007;120:456–67. [PubMed: 17227794]
17. Jiang W, et al. An FF domain-dependent protein interaction mediates a signaling pathway for growth factor-induced gene expression. *Mol Cell* 2005;17:23–35. [PubMed: 15629714]
18. Jackson TA, Taylor HE, Sharma D, Desiderio S, Danoff SK. Vascular endothelial growth factor receptor-2: counter-regulation by the transcription factors, TFII-I and TFII-IRD1. *J Biol Chem* 2005;280:29856–63. [PubMed: 15941713]
19. Roy AL. Biochemistry and biology of the inducible multifunctional transcription factor TFII-I. *Gene* 2001;274:1–13. [PubMed: 11674993]
20. Francke U. Williams-Beuren syndrome: genes and mechanisms. *Hum Mol Genet* 1999;8:1947–54. [PubMed: 10469848]
21. Roy AL. Signal-induced functions of the transcription factor TFII-I. *Biochim Biophys Acta* 2007;1769:613–21. [PubMed: 17976384]
22. Patterson C, et al. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. *J Biol Chem* 1995;270:23111–8. [PubMed: 7559454]
23. Minami T, Rosenberg RD, Aird WC. Transforming growth factor-beta 1-mediated inhibition of the flk-1/KDR gene is mediated by a 5'-untranslated region palindromic GATA site. *J Biol Chem* 2001;276:5395–402. [PubMed: 11098056]
24. Minami T, et al. Interaction between hex and GATA transcription factors in vascular endothelial cells inhibits flk-1/KDR-mediated vascular endothelial growth factor signaling. *J Biol Chem* 2004;279:20626–35. [PubMed: 15016828]
25. Cantor AB, Orkin SH. Hematopoietic development: a balancing act. *Curr Opin Genet Dev* 2001;11:513–9. [PubMed: 11532392]
26. Grogan JL, Locksley RM. T helper cell differentiation: on again, off again. *Curr Opin Immunol* 2002;14:366–72. [PubMed: 11973136]
27. Pai SY, Truitt ML, Ho IC. GATA-3 deficiency abrogates the development and maintenance of T helper type 2 cells. *Proc Natl Acad Sci U S A* 2004;101:1993–8. [PubMed: 14769923]
28. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. *Cell* 2006;127:1041–55. [PubMed: 17129787]
29. Su ZJ, et al. A vascular cell-restricted RhoGAP, p73RhoGAP, is a key regulator of angiogenesis. *Proc Natl Acad Sci U S A* 2004;101:12212–7. [PubMed: 15302923]
30. Arthur WT, Petch LA, Burrige K. Integrin engagement suppresses RhoA activity via a c-Src-dependent mechanism. *Curr Biol* 2000;10:719–22. [PubMed: 10873807]
31. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. *J Cell Sci* 2001;114:853–65. [PubMed: 11181169]
32. Sheibani N, Frazier WA. Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype. *Mol Biol Cell* 1998;9:701–13. [PubMed: 9529372]
33. Numaguchi Y, et al. Caldesmon-dependent switching between capillary endothelial cell growth and apoptosis through modulation of cell shape and contractility. *Angiogenesis* 2003;6:55–64. [PubMed: 14517405]
34. Polte TR, Eichler GS, Wang N, Ingber DE. Extracellular matrix controls myosin light chain phosphorylation and cell contractility through modulation of cell shape and cytoskeletal prestress. *Am J Physiol Cell Physiol* 2004;286:C518–28. [PubMed: 14761883]
35. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. *Proc Natl Acad Sci U S A* 1995;92:905–9. [PubMed: 7846076]

36. Stalmans I, et al. Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. *J Clin Invest* 2002;109:327–36. [PubMed: 11827992]
37. Mammoto T, et al. Angiotensin-1 requires p190RhoGAP to protect against vascular leakage *in vivo*. *J Biol Chem*. 2007
38. Singh H, Medina KL, Pongubala JM. Contingent gene regulatory networks and B cell fate specification. *Proc Natl Acad Sci U S A* 2005;102:4949–53. [PubMed: 15788530]
39. Swiers G, Patient R, Loose M. Genetic regulatory networks programming hematopoietic stem cells and erythroid lineage specification. *Dev Biol* 2006;294:525–40. [PubMed: 16626682]
40. Gottgens B, et al. Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors. *Embo J* 2002;21:3039–50. [PubMed: 12065417]
41. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. *Cell* 2006;126:677–89. [PubMed: 16923388]
42. Clark ER, Clark EL. Microscopic observations on the growth of blood capillaries in the living mammal. *Am J Anat* 1938;64:251–301.
43. Carmeliet P, Tessier-Lavigne M. Common mechanisms of nerve and blood vessel wiring. *Nature* 2005;436:193–200. [PubMed: 16015319]
44. Pelham RJ Jr, Wang Y. Cell locomotion and focal adhesions are regulated by substrate flexibility. *Proc Natl Acad Sci U S A* 1997;94:13661–5. [PubMed: 9391082]
45. Wang N, et al. Cell prestress. I. Stiffness and prestress are closely associated in adherent contractile cells. *Am J Physiol Cell Physiol* 2002;282:C606–16. [PubMed: 11832346]
46. Yung CW, et al. Transglutaminase crosslinked gelatin as a tissue engineering scaffold. *J Biomed Mater Res A* 2007;83:1039–46. [PubMed: 17584898]
47. Connor KM, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. *Nat Med* 2007;13:868–73. [PubMed: 17589522]




Fig. 1. TFII-I and GATA2 control VEGFR2 expression via p190RhoGAP

a) VEGFR2 and TFII-I mRNA levels in cells treated with TFII-I siRNA or lentiviral vectors (virus) relative to control cells (*, $p < 0.05$; unpaired Student's t-test is used throughout). **b)** Immunoblots showing VEGFR2, TFII-I, p190RhoGAP, and GAPDH protein levels in cells treated with TFII-I or p190RhoGAP siRNAs, or both. **c)** Immunofluorescence micrographs showing GATA2 distribution and nuclear DAPI staining in control and p190RhoGAP knockdown cells cultured with 0.3% serum (bar, 5 μ m). **d)** VEGFR2 mRNA level in cells transfected with p190RhoGAP siRNA alone or with GATA2 siRNA (*, $p < 0.01$). VEGFR2 promoter activities (**e**) and mRNA levels (**f**) in cells transfected with GATA2 or TFII-I siRNA alone or in combination (*, $p < 0.01$; **, $p < 0.05$). **g)** ChIP analysis showing VEGFR2 promoter

co-immunoprecipitating with GATA2 or TFII-I antibodies in cells transfected with *TFII-I* or *GATA2* siRNA (Ct, control; n=3; error bars = s.e.m. throughout).




Fig. 2. Matrix elasticity controls *VEGFR2* expression via TFII-I and GATA2

a) Immunofluorescence micrographs showing GATA2 and TFII-I distribution in HMVE cells cultured on the fibronectin-coated gels of different stiffness (Young's moduli of 150 and 4000 Pa) in EBM2 with 0.3% serum (bar, 5 μ m). **b**) *VEGFR2* mRNA level in HMVE cells cultured on rigid fibronectin-coated glass or the gels of different elasticity (150, 1000 and 4000 Pa; normalized to that in cells on the softest gels; *, $p < 0.01$, **, $p < 0.05$). **c**) *VEGFR2* mRNA levels in HMVE cells on soft gels (150 Pa) transfected with *TFII-I* or *GATA2* siRNA alone, or in combination (normalized to cells on the stiffest gels; *, $p < 0.01$). **d**) *VEGFR2* mRNA levels in HMVE cells on soft gels transfected with *p190rhoGAP* or *GATA2* siRNA alone, or in combination (normalized to cells on stiffest gels; *, $p < 0.01$). Error bars represent s.e.m. of 3 replica experiments.




Fig. 3. Antagonism between GATA2 and TFII-I controls capillary cell migration and tube formation *in vitro*

a) The motility of HMVE cells transfected with human siRNAs or transduced with lentiviral vectors encoding *GATA2* or *TFII-I*, alone or in combination, was quantitated using the Transwell migration assay (*, $p < 0.01$). Where indicated, VEGF (10 ng/ml) was added to the lower chamber and SU5416 was added in both chambers. Error bars represent s.e.m. of 3 replica experiments. **b)** Micrographs showing *in vitro* tube formation induced by VEGF (10 ng/ml) in HMVE cells transfected with siRNAs or transduced with lentiviral vectors encoding *GATA2* or *TFII-I*, alone or in combination.




Fig. 4. Matrix elasticity controls vessel formation via TFII-I and GATA2 *in vivo*
 Light (H&E-stained) (**a,b top**), immunofluorescence micrographs (**a,b bottom**) and vessel densities per high power field (**c,d**) showing cell infiltration and VEGFR2 expression in Matrigel with different elasticity implanted in mice for 7 days without (**a,c**) or with *TFII-I* or *Gata2* siRNAs (**b,d**) (bar, 25 μ m). The number of VEGFR2-positive blood vessels was normalized to that in the 700Pa gels in (**c**) and to that in gels treated with control siRNA in (**d**) (n=6, mean \pm S.E.M., *, $p < 0.01$).




Fig. 5. TFII-I, GATA2, and p190RhoGAP regulate retinal vessel formation *in vivo*
a) Confocal fluorescence micrographs showing projected images of vessels stained with Alexa 594-isolectin in the retina of a control mouse eye versus eyes transfected with *TFII-I*, *Gata2*, or *p190RhoGAP* siRNAs (bar = 0.1 mm). **b)** Confocal fluorescence micrographs showing projected images of vessels stained with Alexa 594-isolectin in the retina of a control mouse eye versus eyes overexpressed *TFII-I* or *GATA2*, alone or both in combination (bar = 0.1 mm).